Avenanthramide-C as Alzheimer's Disease-Modifying Therapy: Early and Sustained Intervention Prevents Disease...

Area of Science:

• Neuroscience
• Pharmacology
• Natural Product Chemistry

Background:

• Current Alzheimer's disease (AD) treatments offer modest efficacy and do not halt progression.
• Natural compounds are being investigated as alternative AD interventions.
• Previous studies indicated short-term Avenanthramide-C (Avn-C) benefits in AD models.

Purpose of the Study:

• To evaluate the long-term efficacy of sustained Avenanthramide-C (Avn-C) treatment.
• To assess Avn-C's impact on cognitive function and neuropathology in AD mouse models.
• To investigate the molecular mechanisms underlying Avn-C's therapeutic effects.

Main Methods:

• Administered oral Avenanthramide-C (Avn-C) for three months to 5xFAD and Tg2576 AD mouse models.
• Assessed cognitive function, long-term potentiation (LTP), and molecular markers of AD pathology.
• Investigated effects on AMPK activation, caspase-3, GSK3β, NF-κB signaling, and microglial function.

Main Results:

• Sustained Avn-C treatment preserved cognitive function and LTP.
• Avn-C inhibited caspase-3 and GSK3β, reducing amyloid and tau pathology.
• Maintained anti-inflammatory effects by suppressing NF-κB and promoting microglial phagocytosis.

Conclusions:

• Early and sustained Avenanthramide-C (Avn-C) treatment shows potential for slowing Alzheimer's disease progression.
• Avn-C modulates multiple key pathological pathways, including amyloid and tau accumulation and neuroinflammation.
• Avn-C may offer a novel therapeutic strategy by targeting early neurodegenerative processes in Alzheimer's disease.